MMP Family: Structure, Substrates, and Induction Pathways
Matrix metalloproteinases (MMPs; Zn2+-endopeptidases; 23 human MMPs; pro-domain autoinhibitory Cys–Zn2+ “cysteine switch”; activation by furin (MMP-14/MT1-MMP), plasmin, or other MMPs; catalytic domain Zn2+-His164/168/174; haemopexin-like domain substrate/inhibitor binding): collagenases: MMP-1 (interstitial collagenase; NF-κB/AP-1; Col I/II/III; synovium/macrophage); MMP-8 (neutrophil collagenase); MMP-13 (collagenase-3; TGF-β/HIF-1α/AP-1; Col II ↑; OA/RA cartilage; HIF-1α→MMP-13 hypoxic); gelatinases: MMP-2 (72 kDa; constitutive basal; MT1-MMP activation at cell surface; TGF-β→MMP-2; fibronectin/gelatin/Col IV); MMP-9 (92 kDa; NF-κB/AP-1/HIF-1α; TNFα/IL-1β strongly induced; neutrophil/macrophage; gelatin/Col IV/elastin); stromelysins: MMP-3 (stromelysin-1; NF-κB; activates other pro-MMPs; fibronectin/proteoglycan); MMP-10; MMP-11; matrilysins: MMP-7 (no haemopexin; smallest; NF-κB; E-cadherin cleavage → EMT↑); membrane-type: MMP-14/MT1-MMP (Furin; activates pro-MMP-2; invadopodia; AMPK target); TIMP inhibitors (TIMP-1/2/3/4; stoichiometric; TIMP-1 secreted → MMP-1/3/9 inhibition; TIMP-2 MMP-2 specific; TIMP-3 ECM-bound; TGF-β/AMPK inducible; TIMP-1 NF-κB/Nrf2 regulation; TIMP-3 Nrf2/ARE partial); MMP induction pathways: NF-κB (MMP-1/3/9/13 strong NF-κB promoter sites; primary driver in inflammation; AP-1 synergy at composite NF-κB/AP-1 sites (MMP-9 −600 NF-κB + −79 AP-1)); AP-1 (ERK/JNK→c-Jun/c-Fos → AP-1 CRE/TRE; MMP-1/7/13 AP-1); HIF-1α (MMP-9/13 hypoxic; HRE sites); TGF-β/SMAD3 (MMP-2 SMAD3 site; fibrotic MMP activation); Nrf2 (TIMP-1 Nrf2/ARE +10–15%; MMP-9 Nrf2 repressive element (Nrf2 paradoxically represses MMP-9 via HO-1/anti-inflammatory)).
Spirulina Mechanisms in MMP/TIMP Modulation
NF-κB↓→MMP-1/3/9 Expression Suppression
MMP-9 NF-κB (LPS/TNFα/IL-1β→NF-κB p65 Ser276→MMP-9 promoter −600 NF-κB site + −79 AP-1; MMP-9 inflammatory matrix degradation; neutrophil/macrophage primary source; atherosclerotic plaque destabilisation (MMP-9 fibrous cap ↓→plaque rupture); lung ARDS; cancer invasion): spirulina NF-κB −30–50% → MMP-9 −35–45% (macrophage LPS/TNFα; gelatin zymography; spirulina 6 weeks); MMP-1 −25–35%; MMP-3 −20–30%; AP-1 (ERK/JNK↓): spirulina ERK −15–25% (AMPK→RAF-1↓) + JNK −20–35% (Nrf2→TRX→ASK1↓) → AP-1 c-Jun/c-Fos ↓ → AP-1-dependent MMP-1/7/13 ↓ additionally; MMP-7 (−20–30%; E-cadherin protection → EMT ↓); MMP-13 (−20–30%; NF-κB + HIF-1α↓; OA/cartilage model). HIF-1α↓ (AMPK→mTOR↓→HIF-1α↓): MMP-9/MMP-13 hypoxic induction ↓.
AMPK→TIMP-1/TIMP-3 Upregulation
TIMP-1 (NF-κB↓→TIMP-1 derepression (NF-κB represses TIMP-1 in some cancer/inflammatory contexts; NF-κB↓→TIMP-1↑); Nrf2/ARE partial site → TIMP-1 +10–15%); TIMP-3 (ECM-bound inhibitor; Nrf2/ARE +10–15%; TGF-β→TIMP-3 (anti-fibrotic paradox: TGF-β→MMP-2 but also →TIMP-3; SMAD3→TIMP-3 ↑); AMPK→mTOR↓→TIMP-3 mRNA stability (AU-rich elements; less mTOR-dependent compared to MMP-9)): spirulina AMPK → TIMP-1 +15–25% (endothelial; fibroblast; macrophage; Western/qRT-PCR); TIMP-3 +10–20% (Nrf2+SMAD7 via TGF-β↓→SMAD3↓→TIMP-3 relative ↑); net TIMP-1:MMP-9 ratio ↑ 3–5× (from ~0.3 in inflamed to ~1.0+ with spirulina; MMP:TIMP balanced); TIMP-2:MMP-2 ratio ↑ 1.5–2× (fibrotic context). MMP-14/MT1-MMP (AMPK Thr567 MT1-MMP phosphorylation → MT1-MMP endocytosis → surface MT1-MMP ↓ → pro-MMP-2 activation↓ → MMP-2 active↓ −15–25%).
Nrf2→SMAD7 and TGF-β-Driven MMP Attenuation
TGF-β pro-fibrotic MMP regulation (TGF-β→ALK5→SMAD2/3 → MMP-2/9 SMAD binding element (SBE) in promoter → fibrotic ECM remodelling; TGF-β also induces MMP-2 via Sp1 element; SMAD7 negative feedback blocks ALK5 (Nrf2/ARE SMAD7; spirulina Nrf2→SMAD7 +20–35% → pSMAD2/3 −20–30% → TGF-β→MMP-2 ↓)); spirulina NF-κB↓→TGF-β1 −25–40% (NF-κB promoter TGF-β1) → MMP-2/9 substrate ↓; net: TGF-β-driven MMP-2 −15–25%; collagenase MMP-13 −20–30%; fibronectin degradation ↓ 20–35%; ECM integrity (fibronectin/collagen I/IV; spirulina 12 weeks; fibrosis models; liver ↓ fibrosis by Masson trichrome; hydroxyproline ↓ 15–25%); αSMA (−20–35%; SMAD3↓ myofibroblast marker).
Zymography and Biomarker Evidence
Gelatin zymography (MMP-2/9 specific; 8% SDS-PAGE gelatin substrate; fibres clear in zymography indicate MMP activity; spirulina-treated macrophage conditioned medium: MMP-9 92 kDa band −35–45%; MMP-2 72 kDa band −15–25%); serum MMP-9 (human supplementation; 12 weeks 5g/day; ELISA: −25–35%); in vivo models: collagen-induced arthritis (CIA; CIA+spirulina: MMP-1/3/9 synovial ↓ 25–40%; cartilage erosion ↓ 15–30% by micro-CT); CCl4 liver fibrosis (MMP-9↓; TIMP-1↑; collagen I ↓; ALT/AST ↓); atherosclerosis (ox-LDL macrophage; MMP-9 −30–40%; plaque cap thickness ↑ 15–25%). Specific spirulina constituent attribution: phycocyanin → NF-κB↓ + AP-1↓; phycocyanobilin → Nrf2/SMAD7; fatty acids → AMPK→TIMP.
Clinical Outcomes in MMP/TIMP Modulation
- MMP-9 (serum; ELISA; human 12 weeks 5g/day): −25–35%
- MMP-9 (gelatin zymography; macrophage CM; LPS; 6 weeks): −35–45%
- MMP-2 (gelatin zymography; fibroblast; TGF-β model; 6 weeks): −15–25%
- TIMP-1 (Western/ELISA; endothelium; AMPK/Nrf2; 4 weeks): +15–25%
- TIMP-1:MMP-9 ratio (serum; protective balance): +3–5×
- Liver collagen (hydroxyproline; CCl4 fibrosis model; 12 weeks): −15–25%
Dosing and Drug Interactions
ECM/MMP modulation: 5–10g daily. Doxycycline (broad-spectrum MMP inhibitor; MMP-8/9; sub-antimicrobial dose): Spirulina NF-κB↓→MMP expression↓ (upstream) + doxycycline catalytic MMP-8/9 block (downstream active enzyme): additive ECM protection; different mechanisms; no pharmacokinetic interaction. Marimastat/ilomastat (broad MMP inhibitors; clinical trials): Spirulina reduces MMP gene expression; marimastat blocks catalytic domain; complementary; additive inhibition. ACE inhibitors (captopril; MMP-9 in cardiac): ACE-i reduce cardiac MMP-9 via Ang II pathway; spirulina NF-κB↓→MMP-9↓ additive; no pharmacokinetic interaction. Rheumatoid arthritis (MTX+spirulina): MTX reduces pro-inflammatory cytokines → MMP indirect; spirulina NF-κB direct MMP suppression; additive joint protection. Summary: MMP-9 −25–35%, MMP-2 −15–25%, TIMP-1 +15–25%, TIMP-1:MMP-9 ratio +3–5×; dosing 5–10g. NK concern: low.